FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

David Potter

Research Profile

Physiology

Intraocular Pressure

Living Beings

Rabbits
Cats

Anatomy

Concepts & Ideas

Drug Dose Response Relationship

Chemicals & Drugs

Procedures

Disorders

Ocular Hypotension

Co-author Network

Publications

TOP 3
Shahid Husain; Yasir Abdul; David E Potter
Non-analgesic effects of opioids: neuroprotection in the retina.
Shahid Husain; David E Potter; Craig E Crosson
Opioid receptor-activation: retina protected from ischemic injury.
Shahid Husain; David E Potter
The opioidergic system: potential roles and therapeutic indications in the eye.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of David Potter (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Shahid Husain; Yasir Abdul; David E Potter
Non-analgesic effects of opioids: neuroprotection in the retina.
Current pharmaceutical design 2012;18(37):6101-8.
2009: Shahid Husain; David E Potter; Craig E Crosson
Opioid receptor-activation: retina protected from ischemic injury.
Investigative ophthalmology & visual science 2009;50(8):3853-9.
2008: Shahid Husain; David E Potter
The opioidergic system: potential roles and therapeutic indications in the eye.
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 2008;24(2):117-40.
2005: Juanita _ Carnes; David E Potter
Bremazocine: a kappa-opioid agonist with potent analgesic and other pharmacologic properties.
CNS drug reviews 2005;11(2):195-212.
2004: David E Potter; Karen R M Russell; Marlina Manhiani
Bremazocine increases C-type natriuretic peptide levels in aqueous humor and enhances outflow facility.
The Journal of pharmacology and experimental therapeutics 2004;309(2):548-53.
2003: Juanita _ Carnes; David E Potter
Delta-opioid agonist-stimulated inositol phosphate formation in isolated, rabbit iris-ciliary bodies: role of G(i/o) proteins and Gbetagamma-subunits.
Experimental eye research 2003;77(6):647-52.
2003: Daniel _ Von Deutsch; Imad K Abukhalaf; Lawrence E. Wineski; Natalia A Silvestrov; Mohamed A Bayorh; David E Potter
Changes in muscle proteins and spermidine content in response to unloading and clenbuterol treatment.
Canadian journal of physiology and pharmacology 2003;81(1):28-39.
2002: Teh Ching Chu; Qing He; David E Potter
Biodegradable calcium phosphate nanoparticles as a new vehicle for delivery of a potential ocular hypotensive agent.
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 2002;18(6):507-14.
2002: Miller J Ogidigben; David E Potter
Pharmacological evidence of a role for prejunctional imidazoline (I(1)) receptors in ocular function.
Current eye research 2002;25(5):267-70.
2002: Juanita _ Carnes; David E Potter
Effect of bremazocine, a kappa-opioid receptor agonist, on inositol phosphate formation in isolated iris-ciliary bodies.
Pharmacology 2002;66(2):100-6.
2002: Karen R M Russell; David E Potter
Dynorphin modulates ocular hydrodynamics and releases atrial natriuretic peptide via activation of kappa-Opioid receptors.
Experimental eye research 2002;75(3):259-70.
2002: Teh Ching Chu; David E Potter
Ocular hypotension induced by electroacupuncture.
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 2002;18(4):293-305.
2002: Miller J Ogidigben; Teh Ching Chu; David E Potter
Naphazoline-induced neuroendocrine changes: increases in ANP and cGMP levels, but suppression of NE, 3H-NE, and cAMP levels in rabbit eyes.
Pharmacology 2002;65(3):155-61.
2002: Imad K Abukhalaf; Daniel _ Von Deutsch; Lawrence E. Wineski; Natalia A Silvestrov; Saare A Abera; Sinafikish W Sahlu; David E Potter
Effect of hindlimb suspension and clenbuterol treatment on polyamine levels in skeletal muscle.
Pharmacology 2002;65(3):145-54.
2002: Juanita _ Carnes; David E Potter
Inhibition of cAMP accumulation by kappa-receptor activation in isolated iris-ciliary bodies: role of phosphodiesterase and protein kinase C.
The Journal of pharmacology and experimental therapeutics 2002;301(2):599-604.
2002: Daniel _ Von Deutsch; Imad K Abukhalaf; Lawrence E. Wineski; R R Roper; HY Aboul-Enein; Douglas _ Paulsen; David E Potter
Distribution and muscle-sparing effects of clenbuterol in hindlimb-suspended rats.
Pharmacology 2002;65(1):38-48.
2002: Lawrence E. Wineski; Daniel _ Von Deutsch; Imad K Abukhalaf; Sidney A Pitts; David E Potter; Douglas _ Paulsen
Muscle-specific effects of hindlimb suspension and clenbuterol in mature male rats.
Cells, tissues, organs 2002;171(2-3):188-98.
2001: Karen R M Russell; Terri T Moore; David E Potter
Elevation of atrial natriuretic peptide levels in aqueous humor of the rabbit by kappa opioid receptor agonists.
Neuropeptides 2001;35(5-6):232-7.
2001: Karen R M Russell; David E Potter
Biphasic alterations of cAMP levels and inhibition of norepinephrine release in iris-ciliary body by bremazocine.
The Journal of pharmacology and experimental therapeutics 2001;298(3):941-6.
2001: Terri T Moore; David E Potter
Kappa opioid agonist-induced changes in IOP: correlation with 3H-NE release and cAMP accumulation.
Experimental eye research 2001;73(2):167-78.
2001: Miller J Ogidigben; David E Potter
Central imidazoline (I(1)) receptors modulate aqueous hydrodynamics.
Current eye research 2001;22(5):358-66.
2001: Miller J Ogidigben; Teh Ching Chu; David E Potter
Naphazoline-induced suppression of aqueous humor pressure and flow: involvement of central and peripheral alpha(2)/I(1) receptors.
Experimental eye research 2001;72(3):331-9.
2000: L Zhou; Winston E Thompson; David E Potter
Functional identification of phosphodiesterase activity in human trabecular meshwork cells.
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 2000;16(4):317-22.
2000: Daniel _ Von Deutsch; Imad K Abukhalaf; Lawrence E. Wineski; HY Aboul-Enein; S A Pitts; B A Parks; Robert A Oster; Douglas _ Paulsen; David E Potter
Beta-agonist-induced alterations in organ weights and protein content: comparison of racemic clenbuterol and its enantiomers.
Chirality 2000;12(8):637-48.
2000: Eugenia Chu; Teh Ching Chu; David E Potter
Mechanisms and sites of ocular action of 7-hydroxy-2-dipropylaminotetralin: a dopamine(3) receptor agonist.
The Journal of pharmacology and experimental therapeutics 2000;293(3):710-6.
2000: Karen R M Russell; D R Wang; David E Potter
Modulation of ocular hydrodynamics and iris function by bremazocine, a kappa opioid receptor agonist.
Experimental eye research 2000;70(5):675-82.
2000: Imad K Abukhalaf; Daniel _ Von Deutsch; B A Parks; Lawrence E. Wineski; Douglas _ Paulsen; HY Aboul-Enein; David E Potter
Comparative analytical quantitation of clenbuterol in biological matrices using GC-MS and EIA.
Biomedical chromatography : BMC 2000;14(2):99-105.
1999: Eugenia Chu; Teh Ching Chu; David E Potter
Potential sites of action of TNPA: a dopamine-2 receptor agonist.
Experimental eye research 1999;69(6):611-6.
1999: Teh Ching Chu; Miller J Ogidigben; David E Potter
8OH-DPAT-Induced ocular hypotension: sites and mechanisms of action.
Experimental eye research 1999;69(2):227-38.
1999: L Zhou; W J Thompson; David E Potter
Multiple cyclic nucleotide phosphodiesterases in human trabecular meshwork cells.
Investigative ophthalmology & visual science 1999;40(8):1745-52.
1999: Miller J Ogidigben; Teh Ching Chu; David E Potter
Peripheral and central effects of naphazoline on ocular hydrodynamics. Involvement of imidazoline receptors, ANP, and Gi proteins.
Annals of the New York Academy of Sciences 1999;881():388-91.
1999: Teh Ching Chu; P Han; G Han; David E Potter
Intraocular pressure lowering by S-allylmercaptocysteine in rabbits.
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 1999;15(1):9-17.
1998: David E Potter; Miller J Ogidigben; Teh Ching Chu
Lisuride acts at multiple sites to induce ocular hypotension and mydriasis.
Pharmacology 1998;57(5):249-60.
1997: Teh Ching Chu; Robin R Socci; Miller J Ogidigben; David E Potter
Potential mechanisms of moxonidine-induced ocular hypotension: role of norepinephrine.
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 1997;13(6):489-96.
1997: Teh Ching Chu; Robin R Socci; David E Potter
Moxonidine-induced inhibition of norepinephrine release in monkey and rabbit ciliary bodies: role of cGMP.
Pharmacology 1997;55(4):211-6.
1996: Teh Ching Chu; Miller J Ogidigben; David E Potter
Oxymetazoline: potential mechanisms of inhibitory effects on aqueous humor dynamics.
Pharmacology 1996;53(4):259-70.
1996: Teh Ching Chu; J L Burch; M A de Paula Brotto; Tony Creazzo; J Han; G Y Han; David E Potter
Elevation of intracellular Ca2+ concentration in rabbit nonpigmented ciliary epithelial cells by allicin.
Comparative biochemistry and physiology. Part C, Pharmacology, toxicology & endocrinology 1996;115(1):89-94.
1996: Teh Ching Chu; W Wong; Charles Gluchowski; B W Hughes; David E Potter
Rilmenidine-induced ocular hypotension: role of imidazoline1 and alpha 2 receptors.
Current eye research 1996;15(9):943-50.
1996: D Wang; David E Potter
Ocular action of an opioid peptide, DPDPE.
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 1996;12(2):131-9.
1995: W R Campbell; David E Potter
Centrally mediated ocular hypotension: potential role of imidazoline receptors.
Annals of the New York Academy of Sciences 1995;763():463-85.
1994: W R Campbell; David E Potter
The central effects of moxonidine on intraocular pressure and its antagonism by L-659, 066 and L-657, 743 in the rabbit.
Progress in neuro-psychopharmacology & biological psychiatry 1994;18(6):1051-61.
1994: Miller J Ogidigben; Teh Ching Chu; David E Potter
Alpha-2 adrenoceptor mediated changes in aqueous dynamics: effect of pertussis toxin.
Experimental eye research 1994;58(6):729-36.
1994: Miller J Ogidigben; Teh Ching Chu; David E Potter
Ocular actions of moxonidine: a possible role for imidazoline receptors.
The Journal of pharmacology and experimental therapeutics 1994;269(3):897-904.
1994: W R Campbell; David E Potter
Potential role of imidazoline (I1) receptors in modulating aqueous humor dynamics.
Journal of ocular pharmacology 1994;10(1):393-402.
1993: Miller J Ogidigben; Teh Ching Chu; David E Potter
Ocular hypotensive action of a dopaminergic (DA2) agonist, 2,10,11-trihydroxy-N-n-propylnoraporphine.
The Journal of pharmacology and experimental therapeutics 1993;267(2):822-7.
1993: David E Potter; Miller J Ogidigben; A R Heath
Ocular actions of an octahydrobenzo[f]quinoline: Ha117.
European journal of pharmacology 1993;236(1):61-8.
1993: Teh Ching Chu; Miller J Ogidigben; J C Han; David E Potter
Allicin-induced hypotension in rabbit eyes.
Journal of ocular pharmacology 1993;9(3):201-9.
1993: Miller J Ogidigben; David E Potter
Comparative effects of alpha-2 and DA-2 agonists on intraocular pressure in pigmented and nonpigmented rabbits.
Journal of ocular pharmacology 1993;9(3):187-99.
1992: Craig E Crosson; A R Heath; G W DeVries; David E Potter
Pharmacological evidence for heterogeneity of ocular alpha 2 adrenoceptors.
Current eye research 1992;11(10):963-70.
1991: David E Potter; Miller J Ogidigben
Medetomidine-induced alterations of intraocular pressure and contraction of the nictitating membrane.
Investigative ophthalmology & visual science 1991;32(10):2799-805.
1990: David E Potter; J A Burke; Miller J Ogidigben
Ocular inhibitory effects of the dopamine DA2 agonist (Ha-118) in cats and rabbits.
Journal of autonomic pharmacology 1990;10(3):153-61.
1990: Craig E Crosson; J A Burke; Ming Fai Chan; David E Potter
Prejunctional adrenoceptor activity of N-0437: a relatively selective DA2 dopamine receptor agonist.
European journal of pharmacology 1990;178(3):351-5.
1990: David E Potter; Craig E Crosson; A R Heath; Miller J Ogidigben
Functional evidence for heterogeneity of ocular alpha 2-adrenoceptors.
Proceedings of the Western Pharmacology Society 1990;33():257-60.
1990: Craig E Crosson; J A Willis; David E Potter
Effect of the calcium antagonist, nifedipine, on ischemic retinal dysfunction.
Journal of ocular pharmacology 1990;6(4):293-9.
1990: David E Potter; Craig E Crosson; A R Heath; Miller J Ogidigben
Review: alpha 2 and DA2 agonists as antiglaucoma agents: comparative pharmacology and clinical potential.
Journal of ocular pharmacology 1990;6(3):251-7.
1988: David E Potter; D J Shumate; H Bundgaard; V H Lee
Ocular and cardiac beta-antagonism by timolol prodrugs, timolol and levobunolol.
Current eye research 1988;7(8):755-9.
1988: David E Potter; J A Burke
LY141865: a relatively selective DA2 agonist with complex ocular activity.
Journal of ocular pharmacology 1988;4(1):19-28.
1987: Craig E Crosson; J A Burke; Ming Fai Chan; David E Potter
Ocular effects of a N,N-disubstituted 5-OH aminotetralin (N-0437): evidence for a dual mechanism of action.
Current eye research 1987;6(11):1319-26.
1987: J A Burke; David E Potter
Aporphine derivatives affect ocular function in diverse ways.
Current eye research 1987;6(10):1227-36.
1987: David E Potter; D J Shumate
Cianergoline lowers intraocular pressure in rabbits and monkeys and inhibits contraction of the cat nictitans by suppressing sympathetic neuronal function.
Journal of ocular pharmacology 1987;3(4):309-21.
1986: J A Burke; David E Potter
Ocular effects of a relatively selective alpha 2 agonist (UK-14, 304-18) in cats, rabbits and monkeys.
Current eye research 1986;5(9):665-76.
1986: J A Burke; David E Potter
The ocular effects of xylazine in rabbits, cats, and monkeys.
Journal of ocular pharmacology 1986;2(1):9-21.
1985: David E Potter; J A Burke; J R Temple
Forskolin suppresses sympathetic neuron function and causes ocular hypotension.
Current eye research 1985;4(2):87-96.
1985: F W Chang; J A Burke; David E Potter
Mechanism of the ocular hypotensive action of ketanserin.
Journal of ocular pharmacology 1985;1(2):137-47.
1985: David E Potter; J A Burke
Does B-HT 920 lower intraocular pressure in cats by interacting with alpha 2- and/or DA2 adrenoceptors?
Journal of ocular pharmacology 1985;1(1):29-45.
1984: David E Potter; J A Burke
An in vivo model for dissociating alpha 2-and DA2-adrenoceptor activity in an ocular adnexa: utility of the cat nictitating membrane preparation.
Current eye research 1984;3(11):1289-98.
1984: J A Burke; F W Chang; David E Potter
Effects of aminotetralins on intraocular pressure and pupillary function in rabbits.
Journal of autonomic pharmacology 1984;4(3):185-92.
1984: David E Potter; J A Burke; F W Chang
Alteration in ocular function induced by phenylethylamine analogs of dopamine.
Current eye research 1984;3(6):851-9.
1984: David E Potter; J A Burke; F W Chang
Ocular hypotensive action of ergoline derivatives in rabbits: effects of sympathectomy and domperidone pretreatment.
Current eye research 1984;3(2):307-14.
1982: David E Potter; J A Burke
Effects of ergoline derivatives on intraocular pressure and iris function in rabbits and monkeys.
Current eye research 1982;2(5):281-8.